Theralase Technologies Inc. (TSXV:TLT)

Market Cap	51.74M -8.5%
Revenue (ttm)	857.91K -9.6%
Net Income	-3.68M
EPS	-0.01
Shares Out	295.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.1800
Previous Close	0.1750
Day's Range	0.1800 - 0.1800
52-Week Range	0.1450 - 0.4100
Beta	0.59
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Theralase Technologies

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Roger Dumoulin-White
• Employees: 20
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: TLT

Financial Performance

In 2025, Theralase Technologies's revenue was 816,468, a decrease of -20.99% compared to the previous year's 1.03 million. Losses were -4.12 million, -3.18% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 13, 2026

Data Sources Report a data error